Ab&B Bio-Tech Announces Strategic Cooperation with Walvax Hong Kong for Global Expansion of Influenza Vaccine

Key Points of the Announcement

• Strategic Cooperation Signed: Ab&B Bio-Tech CO., LTD. JS (“Ab&B Bio-Tech” or “the Company”) has entered into a strategic cooperation agreement with Walvax Hong Kong Limited (“Walvax Hong Kong”) on March 13, 2026.
• Focus on Overseas Markets: The partnership aims to accelerate the overseas registration, sales, and commercialization of Ab&B Bio-Tech’s vaccines, particularly the trivalent subunit influenza vaccine, Huierkangxin 3.
• Product Highlight: Huierkangxin 3 is the first and only trivalent subunit influenza vaccine in China approved for all populations aged 6 months and above. It was approved for marketing in January 2026.
• Target Markets: The agreement will leverage Walvax Hong Kong’s established international distribution networks to expand into Southeast Asia, Latin America, the Middle East, and other Southern Hemisphere markets.
• Strategic Partner Background: Walvax Hong Kong is a wholly-owned subsidiary of Walvax Biotechnology Co., Ltd., a leading vaccine producer in China with a strong international presence.

Details and Potential Share Price Impact

The announcement of this strategic cooperation is significant for Ab&B Bio-Tech’s future growth trajectory and could be seen as a price-sensitive development for shareholders and potential investors. Here’s why:

• International Growth Potential: By partnering with Walvax Hong Kong, a company known for its international operating experience and robust market resources, Ab&B Bio-Tech is positioning itself to rapidly scale its commercial operations outside China. This move could open up substantial new revenue streams in high-growth international markets.
• Product Differentiation: The core product, Huierkangxin 3, is currently unique in China as the only trivalent subunit influenza vaccine approved for everyone aged 6 months and above. The product’s recent approval and its applicability to a broad population segment could drive strong demand, both domestically and overseas.
• Market Expansion: Access to Southeast Asia, Latin America, and the Middle East—regions with large and often under-vaccinated populations—could provide significant business opportunities and accelerate Ab&B Bio-Tech’s revenue and profit growth.
• Strategic Fit: Walvax Hong Kong’s established distribution channels and years of operational experience are expected to greatly reduce the go-to-market time and risk for Ab&B Bio-Tech’s products, which is a key advantage for a company seeking rapid international expansion.
• Pending Definitive Agreement: It is important to note that the current announcement represents a framework cooperation agreement. The actual business cooperation is subject to the conclusion of a definitive business agreement in the future. Investors should monitor for further updates, as the finalization of a binding agreement could be a major catalyst for the share price.
• No Immediate Listing Rule Implications: The agreement does not currently constitute a notifiable or connected transaction under Hong Kong Stock Exchange regulations. However, should a definitive agreement be reached, further disclosures will be made as required.

Board and Management

The announcement was made under the authority of Mr. AN Youcai, Executive Director, Chairman of the Board, and General Manager of Ab&B Bio-Tech. The Board comprises a mix of executive, non-executive, and independent non-executive directors.

What Shareholders Should Know

• Potential Share Price Catalyst: The strategic cooperation for international expansion—if successfully executed—could result in significant revenue and profit growth, and may positively impact the Company’s share price.
• Key Risks: Shareholders are advised that the cooperation is still at the strategic agreement stage and subject to the signing of a definitive business agreement. There is no certainty that all contemplated transactions will proceed as planned.
• Further Announcements: The Company will provide updates as appropriate if and when a definitive business agreement is signed.
• Investor Caution: Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company until further details are released.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation regarding the securities of Ab&B Bio-Tech CO., LTD. JS. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The information is based on the company’s official announcement dated March 13, 2026, and may be subject to change as further details emerge.

View AB&B BIO-TECH-B Historical chart here